Since its identification as a driver of tumour progression and malignancy several FAK inhibitors have been explored within the clinic (please also see Table 1 for a non-exhaustive summary of clinical approaches to target FAK and other molecules regulating the TME). This evidence concerns the gene PTK2 and neoplasm.